In this episode Dr. Gillian Beauchamp sits down with Dr. Laurie Halmo discuss the challenges of making informed recommendations in regard to use of substances during pregnancy.
In this episode Dr. Gillian Beauchamp sits down with Dr. John Downs to discuss recommendations for at risk occupational PFAS testing (Aviation fire fighters, certain agricultural workers (exposure to “ bio sludge” , workers exposed to organofluorines, ski waxers) and challenges of generalized testing.
In this episode Dr. Gillian Beauchamp sits down with Dr. Albert Garcia Romeu to discuss the history of psychedelic use, current treatment protocols and research on using psychedelics to support recovery from substance use disorders.
In this episode Dr. Gillian Beauchamp sits down with Dr. Michael Twiner and Dr. Brett Johnson to discuss harmful algal blooms (HABs) such as inhalation toxicity from Red Tide, neurotoxic shellfish toxicity, diarrheal shellfish poisoning, and amnestic shellfish toxicity.
In this episode Dr. Gillian Beauchamp sits down with Dr. Michael Toce to discuss naloxone access laws, increased community availability of naloxone and who still doesn’t have access to naloxone. They also discuss the difference between naloxone and nalmefene and the future of nalmefene.
In this episode Dr. Gillian Beauchamp sits down with Dr. Kevin Wenzel, PhD to discuss the importance of family involvement including identifying substance use disorder, seeking treatment and providing support during treatment.
In this episode Dr. Gillian Beauchamp sits down with Jonathan Jarry MSc to discuss trends in health related pseudoscience and our role in fighting misinformation.
In this episode Dr. Gillian Beauchamp sits down with Dr. Andrew Stolbach to discuss the mechanishm of action, toxicity and management of checkpoint inhibitors (immunotherapeutic agents used in the treatment of cancer).
In this episode Dr. Gillian Beauchamp sits down with Dr. Joshua Trebach to discuss the benefits and drawbacks of utilizing social media to increase awareness and promote medical toxicology.
In this episode Dr. Gillian Beauchamp sits down with Dr. Filza Hussain to discuss transplant organ allocation in patients who have organ failure secondary to a suicide attempt.
In this episode Dr. Gillian Beauchamp sits down with Dr. Matthew Salzman discusses the complications associated with the use of illicit fentanyl containing xylazine from wounds to withdrawal.
In this episode Dr. Gillian Beauchamp sits down with Dr. Alan Wolfe to discuss the possible clinical effects of POPs (Persistent Organic Pollutants) and PFAS (Per and polyfluoroalkyl substances).
In this episode Dr. Gillian Beauchamp sits down with Dr. Travis Olives to discuss gap junctions and cardiac effects of bupropion toxicity.
In this episode Dr. Gillian Beauchamp sits down with Dr. Stephanie Weiss to discuss HERG channel blockade, QTc prolongation and cardiotoxicity.
In this episode Dr. Gillian Beauchamp sits down with Dr. Meghan Spyres to discuss the evolution of antivenom treatment of North American Pit Viper envenomation with specific discussion of the differences between Fab (CroFab) and F(ab)2 (ANAVIP) antivenom.
In this episode Dr. Gillian Beauchamp sits down with Dr. Christian Tomaszewski to discuss risk factors for delayed cardiomyopathy and mortality after carbon monoxide exposure.
In this episode Dr. Gillian Beauchamp sits down with Dr. Alex Manini to discuss single nucleotide polymorphisms (SNPs) of the Mu receptor and how they may relate to overdose severity of opioid overdose.
In this episode Dr. Gillian Beauchamp sits down with Dr. Fiona Garlich to discuss mechanisms and clinical presentations of aconitine, veratrum alkaloid and grayanotoxin cardiotoxicity.
In this episode Dr. Gillian Beauchamp sits down with Dr. Robert Haley to discuss Gulf War Illness and what caused over 100,000 people to become ill during and after the Gulf War. Dr. Haley describes the gene-environment interaction between PON-1 polymorphism and exposure to sarin gas.
In this episode Dr. Gillian Beauchamp sits down with Dr. Spencer Greene to discuss his recent case series of antimuscarninic delirium treated with rivastigmine in the setting of physostigmine shortages.
In this episode Dr. Gillian Beauchamp sits down with Dr. Tricia Wright to discuss risk factors leading to methamphetamine use disorder, associated complications in pregnancy and management of substance use disorder in pregnant and postpartum patients.
In this episode Dr. Gillian Beauchamp sits down with Dr. Tricia Wright to discuss the known and theoretical risks of cannabis use during pregnancy and lactation.
In this episode Dr. Gillian Beauchamp sits down with Dr. Mishka Terplan to discuss stigma, discrimination and prejudice in relation to substance use in pregnancy.
In this episode Dr. Gillian Beauchamp sits down with Dr. Lori Devlin to discuss Neonatal Abstinence Syndrome (NAS), Neonatal Opioid Withdrawal Syndrome (NOWS) and the treatment of NOWS.
In this episode Dr. Gillian Beauchamp sits down with Dr. Kurt Kleinschmidt to discuss the differences between dependence, addiction, and substance use disorder and how it relates to medication associated treatment (MAT).
In this episode Dr. Gillian Beuachamp sits down with Assistant Chief of Police Matthew Myers to discuss the Drug Recognition Evaluation (DRE) and the Drug Influence Evaluation (DRE) assessments.
In this episode Dr. Gillian Beauchamp sits down with Patrick Harding to discuss anterograde and retrograde ethanol calculations and how they are used in forensic toxicology.
In this episode Dr. Gillian Beauchamp sits down with Dr. Laura Tormoehlen to discuss the nuances of brain death declaration in the toxicology patient
In this episode Dr. Gillian Beauchamp sits down with Dr. Andrew Monte to discuss common nomenclature used in pharmacogenetics and pharmacogenetic factors that impact patient care in the ICU.
In this episode Dr. Gillian Beauchamp sits down with Dr. Brenna Farmer to discuss the process of gaining approval to use medications past their original expiration dates.
